C. Pihoker et al., TREATMENT EFFECTS OF INTRANASAL GROWTH-HORMONE RELEASING PEPTIDE-2 INCHILDREN WITH SHORT STATURE, Journal of Endocrinology, 155(1), 1997, pp. 79-86
Growth hormone-releasing peptide (GHRP)-2 is a synthetic six amino aci
d peptide that is a potent GH secretagogue. Although it shares no stru
ctural homology with GH-releasing hormone, in clinical studies its act
ions on the pituitary release of GH are similar. It is effective when
administered orally and intranasally. For children with GH deficiency,
such noninvasive treatments are most desirable and in need of develop
ment. Fifteen children with short stature participated in this study.
AU of the children had a height <2 S.D. below mean for age, poor heigh
t velocity, delayed bone age, and low serum concentrations of IGF-1. T
hese children had been tested with standard GH secretagogues, e.g. arg
inine, insulin, and L-dopa. Fifty percent of the children were GH defi
cient, the remainder had idiopathic short stature. The children receiv
ed testing with GHRH and GHRP-2 as an acute i.v. bolus of 1 mu g/kg; a
ll children in this study demonstrated a GH response >20 mu g/l. Each
child in this study also demonstrated a GH response >10 mu g/l in resp
onse to intranasal GHRP-2, in the dose range of 5-20 mu g/kg. The chil
dren were administered intranasal GHRP-2, 5-15 mu g/kg, twice a day fo
r 3 months, then three times a day. Fifteen children participated in t
he study for 6 months; six; of the children have participated for 18-2
4 months. Height velocity, serum IGF-1, IGF-binding protein 3 (IGFBP-3
) and GH-binding protein (GHBP) concentrations, and GH responses to GH
RP-2 by i.v. bolus and intranasal spray were examined during treatment
. Height velocity increased h-om 3.7 +/- 0.2 cm/year to 6.1 +/- 0.3 cm
/year at 6 months, 6.0 +/- 0.4 cm/year at 18-24 months. There were no
significant changes in IGF-I or IGF-PBS concentrations, or in acute GH
responses to i.v. or intranasal GHRP-2. GHBP concentrations rose sign
ificantly, from 439 +/- 63 pmol/l to 688 +/- 48 pmol/l. In this study,
intranasal GHRP-2 administration was well tolerated, and produced a m
odest but significant increase in growth velocity.